Open Access<p>Comprehensive assessment of <em>HER2</em> alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance</p>
Author(s) -
Y. Yeh,
ChunHui Lee,
ShangHung Chen,
Chung–Ta Lee,
Yilin Chen,
Bo Lin,
Shio Jean Lin,
RenHao Chan,
JenqChang Lee,
Meng-Ru Shen,
Peng-Chan Lin
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s213247
Subject(s) - colorectal cancer , medicine , university hospital , oncology , cancer , family medicine
Human epidermal growth factor receptor 2 (HER2) is an emerging therapeutic target in colorectal cancer (CRC). Currently, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) have been used to determine HER2-positive CRCs; however, the clinical utility of next-generation sequencing (NGS)-based techniques for determining HER2 status in CRC has been limited. Here, we detail our experience regarding the assessment of HER2 alterations in a CRC cohort.